Compare GECC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | LUNG |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 97.1M |
| IPO Year | 2016 | 2020 |
| Metric | GECC | LUNG |
|---|---|---|
| Price | $5.95 | $2.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $10.75 | $5.38 |
| AVG Volume (30 Days) | 56.4K | ★ 840.0K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $0.92 | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $14.32 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $4.63 | $1.13 |
| 52 Week High | $11.45 | $2.89 |
| Indicator | GECC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 66.28 |
| Support Level | $5.26 | $1.27 |
| Resistance Level | $6.46 | $2.39 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 93.34 | 79.64 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.